Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin
- PMID: 22526913
- DOI: 10.1245/s10434-012-2380-9
Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin
Abstract
Background: Papillary thyroid cancer (PTC) has an excellent prognosis with current treatment methods. However, the rates of locoregional recurrence after initial surgical management remain significant. This study evaluates the effect of reoperative neck dissection for locoregional recurrence of PTC after initial total thyroidectomy and radioiodine therapy on the incidence of cervical recurrence and postoperative serum thyroglobulin (Tg) levels.
Methods: This is a retrospective cohort study conducted in a single academic medical center of patients with recurrent or persistent PTC isolated to the neck after previous total thyroidectomy with or without lymph node dissection and adjuvant I(131) therapy who were treated with reoperative lymph node dissection. Outcomes including operative complications, pathologic findings, and effect of surgery on Tg levels and rates of recurrent disease were analyzed.
Results: From 2001 to 2010, a total of 61 patients had reoperative neck dissections for recurrent cervical PTC with a complication rate of 5 %. Seventy-two percent of patients were clinically free of detectable disease, and 28 % of patients had recurrent, persistent, or newly metastatic disease detected during the follow-up period. All patients had significant decreases in Tg levels, with a median 98 % reduction in preoperative levels. However, only 21 % of patients had an undetectable stimulated Tg (<0.5 ng/mL) during the follow-up period of 15.5 months.
Conclusions: Reoperative treatment of recurrent or persistent PTC can be performed with low complication rates, and Tg levels greatly decrease in most patients; however, few achieve undetectable stimulated Tg.
Similar articles
-
Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.Ann Surg Oncol. 2014 May;21(5):1647-52. doi: 10.1245/s10434-013-3467-7. Epub 2014 Jan 3. Ann Surg Oncol. 2014. PMID: 24385210
-
Papillary Thyroid Carcinoma Recurrence: Low Yield of Neck Ultrasound With an Undetectable Serum Thyroglobulin Level.J Ultrasound Med. 2018 Oct;37(10):2325-2331. doi: 10.1002/jum.14580. Epub 2018 Mar 2. J Ultrasound Med. 2018. PMID: 29498418
-
Serum thyroglobulin level measured after thyroxine withdrawal is useful to predict further recurrence in whole body scan-negative papillary thyroid cancer patients after reoperation.Endocr J. 2012;59(11):1021-30. doi: 10.1507/endocrj.ej12-0128. Epub 2012 Jul 14. Endocr J. 2012. PMID: 22814366
-
Clinical significance of prophylactic central compartment neck dissection in the treatment of clinically node-negative papillary thyroid cancer patients.World J Surg Oncol. 2016 Sep 19;14(1):247. doi: 10.1186/s12957-016-1003-5. World J Surg Oncol. 2016. PMID: 27644091 Free PMC article. Review.
-
Papillary thyroid cancer: medical management and follow-up.Curr Treat Options Oncol. 2005 Jul;6(4):323-38. doi: 10.1007/s11864-005-0036-8. Curr Treat Options Oncol. 2005. PMID: 15967085 Review.
Cited by
-
Risk factors for local recurrence following lateral neck dissection for papillary thyroid carcinoma.Endocrine. 2019 Feb;63(2):310-315. doi: 10.1007/s12020-018-1788-9. Epub 2018 Oct 19. Endocrine. 2019. PMID: 30341706
-
Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.JAMA Surg. 2018 Dec 1;153(12):1098-1104. doi: 10.1001/jamasurg.2018.2659. JAMA Surg. 2018. PMID: 30140908 Free PMC article.
-
The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma.BMC Surg. 2022 Nov 2;22(1):374. doi: 10.1186/s12893-022-01819-1. BMC Surg. 2022. PMID: 36324095 Free PMC article.
-
New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review.J Thyroid Res. 2012;2012:818204. doi: 10.1155/2012/818204. Epub 2012 Dec 24. J Thyroid Res. 2012. PMID: 23320248 Free PMC article.
-
Well-Differentiated Thyroid Cancer Neovasculature Expresses Prostate-Specific Membrane Antigen-a Possible Novel Therapeutic Target.Endocr Pathol. 2017 Dec;28(4):339-344. doi: 10.1007/s12022-017-9500-9. Endocr Pathol. 2017. PMID: 28844117
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous